Leaving This Website

You are leaving this page. This link will take you to a website where our Terms of Use do not apply. EMD Serono, a business of Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.++

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.

OUR TRIALS

Welcome to the tepotinib clinical trial platform. Here, you will find information about tepotinib, an oral drug that blocks the activity of the MET protein in cells, which is currently being studied in clinical trials of cancer that has changes to the MET gene.

Tepotinib is under clinical investigation in several countries of the world. Safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.


Find out more about our tepotinib trials below

 

 

INSIGHT 2: MET-amplified NSCLC with Progression on Osimertinib


LUNG

ADVANCED
METASTATIC

PHASE
2

COMBINATION
THERAPY

A phase 2 clinical study of tepotinib combined with osimertinib in patients with advanced or metastatic Metastatic Having to do with metastasis, which is the spread of cancer from the primary site (place where it started) to other places in the body.1  MET amplified non-small cell lung cancer (NSCLC) with changes in the EGFR gene and resistance Resistance When cancer cells don’t respond to a drug that is usually able to kill or weaken them. Drug resistance may be present before treatment is given or may occur during or after treatment with the drug. Drug resistance can lead to cancer treatment not working or to the cancer coming back.2 to prior osimertinib therapy

ClinicalTrials.gov: NCT03940703

Location: Asia, Europe, North America

Status:

NOW ENROLLING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

PERSPECTIVE: mCRC with Acquired Resistance to Anti-EGFR Therapy Due to MET-amplification


mCRC

ADVANCED
METASTATIC

PHASE
2

COMBINATION
THERAPY

A phase 2 clinical study of tepotinib combined with cetuximab in patients with left-sided metastatic  Left-sided Left-sided colon cancer typically constricts the bowel channel, causing partial blockage. Typical symptoms include constipation, change in bowel habits, and narrow, ribbon-shaped stool when a cancer is low in the rectum. colorectal cancer (mCRC) without changes in RAS/BRAF as a second or third treatment after anti-EGFR antibody targeting treatment Antibody targeting treatment Drugs called monoclonal antibodies block a specific target on the outside of cancer cells. The target might also be in the area around this cancer.4  and with resistance due to MET amplification Amplication Amplication An increase in the number of copies of a gene.5

ClinicalTrials.gov: NCT04515394

Location: Europe, North America

Status:

NOW ENROLLING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

VISION


LUNG

ADVANCED
METASTATIC

PHASE
2

MONOTHERAPY

A phase 2 clinical study of tepotinib in patients with advanced non-small cell lung cancer (NSCLC) with changes in the MET gene.

ClinicalTrials.gov: NCT02864992

Location: Asia, Europe, North America

Status:

ACTIVE, NOT RECRUITING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

1. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastatic. Accessed June 11, 2021. 

2. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/research/annual-plan/scientific-topics/drug-resistance. Accessed June 11, 2021. 

3. National Cancer Institute. SEER Training Modules. https://training.seer.cancer.gov/colorectal/intro/types.html#:~:text=Left%2Dsided%20colon%20cancer%20typically,is%20low%20in%20the%20rectum. Accessed June 11, 2021.

4. Cancer.Net https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy. Accessed June 11, 2021. 

5. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/search/results?swKeyword=gene+amplification.  Accessed June 11, 2021.

Learn More About

Clinical Trials